Reviewing Imation (OTCMKTS:GLAE) & ALT5 Sigma (NASDAQ:ALTS)

ALT5 Sigma (NASDAQ:ALTS) and Imation (OTCMKTS:GLAE) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for ALT5 Sigma and Imation, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
Imation	0	0	0	0	0.00

Earnings and Valuation

This table compares ALT5 Sigma and Imation”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$12.53 million	19.84	-$6.24 million	N/A	N/A
Imation	N/A	N/A	N/A	N/A	N/A

Imation has lower revenue, but higher earnings than ALT5 Sigma.

Volatility and Risk

ALT5 Sigma has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Imation has a beta of 7.44, indicating that its share price is 644% more volatile than the S&P 500.

Profitability

This table compares ALT5 Sigma and Imation’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	133.06%	8.60%	7.10%
Imation	N/A	N/A	N/A

Institutional & Insider Ownership

6.3% of ALT5 Sigma shares are held by institutional investors. 0.7% of ALT5 Sigma shares are held by insiders. Comparatively, 9.2% of Imation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ALT5 Sigma beats Imation on 6 of the 8 factors compared between the two stocks.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

About Imation

GlassBridge Enterprises, Inc., through its subsidiaries, owns and operates an asset management business in the United States. It offers investment advisory services to third party investors through managed funds separate managed accounts. The company was formerly known as Imation Corp. and changed its name to GlassBridge Enterprises, Inc. in February 2017. GlassBridge Enterprises, Inc. was incorporated in 1996 and is headquartered in New York, New York.